

Receipt date: 12/17/2008

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. Sheet 1 of 1

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14875-0164US1	Application No. 10/582,413
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Toshihiko Ohtomo et al.	
(37 CFR §1.98(b))		Filing Date October 26, 2006	Group Art Unit 1643

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	1	1 327 680 A1	07/16/2003	EPO				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	2	Sekimoto et al., "Eradication of Human Myeloma Cells by a Recombinant HLA Class I-Specific Single Chain Fv Diabody," <i>Blood</i> , 102:932a, XP009106629 (Abstract #3469) (November 2003) [Abstract of the American Society of Hematology 45 th Annual Meeting, December 6-9, 2003, San Diego, California]
	3	Sekimoto et al., "A Recombinant HLA Class I-Specific Single Chain Fv Diabody Induces Cell Death in Human Lymphoid Malignancies," <i>Blood</i> , 102:933a, XP002987122 (Abstract #3474) (November 2003) [Abstract of the American Society of Hematology 45th Annual Meeting, December 6-9, 2003, San Diego, California]

Examiner Signature <div style="text-align: center;">/Brad Duffy/</div>	Date Considered <div style="text-align: center;">06/19/2009</div>
---	--

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.